Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: Five-year growth and survival
Journal of Acquired Immune Deficiency Syndromes, Volume 64, No. 5, Year 2013
Notification
URL copied to clipboard!
Description
OBJECTIVES: To describe 5-year growth, survival, and long-term safety among children exposed to nevirapine or zidovudine in an African perinatal prevention trial, HIVNET 012. METHODS: All study children who were alive at the age 18 months were eligible for an extended follow-up study. Children whose families consented were enrolled and evaluated every 6 months from 24 to 60 months. At each visit, history, physical examination, and growth measures were taken. From these measurements, Z scores based on World Health Organization (WHO) standards were computed. Serious adverse event data were collected. Data from the initial and extended follow-up cohorts were included in the analysis. RESULTS: Five hundred twenty-eight study children were alive at the age 18 months, and 491 (426 HIV uninfected and 65 infected) were enrolled into the follow-up study. Both exposed but uninfected children and HIV-infected children were substantially below WHO growth standards for weight and height. Head circumference Z scores for uninfected children were comparable with WHO norms. Five-year survival rates were 93% for uninfected children versus 43% for infected children. Long-term safety and growth outcomes in the 2 study arms were similar. CONCLUSIONS: Both infected and uninfected children in the 5-year HIVNET 012 follow-up showed poor height and weight growth outcomes, underscoring the need for early nutritional interventions to improve long-term growth of all infants born to HIV-infected women in resource-limited settings. Similarly, the low 5-year survival among HIV-infected children support the importance of early initiation of antiretroviral therapy. Both peripartum nevirapine and zidovudine were safe. Copyright © 2013 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Owor, Maxensia A.
Uganda, Kampala
Makerere University
Mwatha, Anthony K.
United States, Seattle
Fred Hutchinson Cancer Research Center
Donnell, Deborah J.
United States, Seattle
Fred Hutchinson Cancer Research Center
Musoke, Philippa Martha
Uganda, Kampala
Makerere University
Mmiro, Francis A.
Uganda, Kampala
Makerere University
Allen, Melissa
United States, Durham
Science Facilitation Department
Jackson, J. Brooks
United States, Baltimore
Johns Hopkins University
Fowler, Mary Glenn
United States, Baltimore
Johns Hopkins University
Guay, Laura A.
United States, Washington, D.c.
The George Washington University
Statistics
Citations: 9
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1097/QAI.0000000000000015
ISSN:
15254135
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Cohort Study
Participants Gender
Female